Small molecule · developed by ASTRAZENECA
AZD0780 is an oral tablet formulation studied in dyslipidaemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06834932 | Phase 2/3 | Dyslipidaemia | Active not recruiting | AZN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dyslipidaemia
Updated Nov 22, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →